Back to top
more

Halozyme Therapeutics (HALO)

(Delayed Data from NSDQ)

$60.63 USD

60.63
1,530,008

+1.91 (3.25%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $60.67 +0.04 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Bristol Myers' (BMY) CAR T-Cell Therapy BLA Review Delayed

by Zacks Equity Research

Bristol Myers (BMY) announces a delay in the FDA review of its BLA for lisocabtagene maraleucel due to COVID-19 pandemic.

J&J (JNJ) Seeks Label Expansion of Darzalex Faspro Combination

by Zacks Equity Research

J&J (JNJ) files regulatory application in the United States and Europe seeking label expansion of Darzalex Faspro in combination with pomalidomide and dexamethasone for treating multiple myeloma.

Kodiak Sciences (KOD) Q3 Earnings Miss, KSI-301 in Focus

by Zacks Equity Research

Kodiak Sciences (KOD) reports wider-than-expected loss in the third quarter of 2020. The company is progressing well with the development of its lead pipeline candidate KSI-301.

Puma (PBYI) Down 8% on Q3 Earnings Lag, Nerlynx Sales View Cut

by Zacks Equity Research

Puma Biotech (PBYI) falls more than 8% as it misses on both earnings and revenues in the third quarter of 2020. The company trims its 2020 revenue guidance for Nerlynx.

Axsome's (AXSM) Q3 Earnings In Line, Pipeline Progresses

by Zacks Equity Research

Axsome (AXSM) earnings meet estimates in the third quarter. The company stretches the timeline for the NDA filing for AXS-05 and AXS-07. Shares fall.

Editas' (EDIT) Earnings Rise Y/Y in Q3, EDIT-101 in Focus

by Zacks Equity Research

Editas' (EDIT) bottom line grows year over year in the third quarter while revenues beat estimates. Stock rises is after-hours trading.

Agios' (AGIO) Q3 Loss Wider Than Expected, Revenues Miss

by Zacks Equity Research

Agios' (AGIO) earnings and revenues fall shy of estimates in the third quarter. The company lifts the lower end of 2020 sales guidance for its leukemia drug Tibsovo. Stock inches up.

ACADIA (ACAD) Q3 Earnings Miss, Nuplazid Drives Revenues Y/Y

by Zacks Equity Research

ACADIA's (ACAD) earnings fall shy of estimates in the third quarter while revenues beat the same. The company maintains its net sales guidance for Nuplazid. Stock dips in after-hours trading.

Halozyme (HALO) Q3 Earnings Top, 2020 View Up, Stock Rises

by Zacks Equity Research

Halozyme (HALO) reports better-than-expected third-quarter results. The company raises outlook for the year anticipating higher royalties.

Halozyme Therapeutics (HALO) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 25.00% and 8.86%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

J&J Seeks Label Expansion of Darzalex Faspro for Amyloidosis

by Zacks Equity Research

J&J (JNJ) files sBLA to the FDA for expanding the label of Darzalex Faspro to treat patients with light chain amyloidosis. Currently, there are no approved therapies for the disease.

Halozyme Therapeutics (HALO) Down 1.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Halozyme (HALO) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Halozyme (HALO) reports lower-than-expected Q2 earnings. Shares down.

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -24.00% and -20.93%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Biotech Stock Q2 Earnings on Aug 10: NVAX, ICPT & More

by Kinjel Shah

Let us take a look at five small biotech companies, NVAX, ICPT, FOLD, RETA, HALO, which are gearing up for their earnings release.

Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Roche's SC Formulation of Perjeta-Herceptin Combo Gets FDA Nod

by Zacks Equity Research

Roche (RHHBY) receives FDA approval for a fixed-dose combination of Perjeta and Herceptin, Phesgo, plus chemotherapy as a treatment for HER2-positive breast cancer.

Why Halozyme Therapeutics (HALO) Stock Might be a Great Pick

by Zacks Equity Research

Halozyme Therapeutics (HALO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Is Halozyme Therapeutics (HALO) Up 1% Since Last Earnings Report?

by Zacks Equity Research

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

J&J's Darzalex Subcutaneous Version Gets Approval in Europe

by Zacks Equity Research

J&J (JNJ) announces approval of subcutaneous formulation of Darzalex for all current MM indications in first-line as well as relapsed/refractory multiple myeloma.

Zacks.com headshot

ACADIA to Merge Two Phase III Studies on Nuplazid for MDD

by Zacks.com

ACADIA (ACAD) to club two late-stage studies on Nuplazid into a single evaluation program for the adjunctive treatment of MDD. Top-line results from the same are expected in Q3.

argenx Up on Positive Data from Pivotal Efgartigimod Study

by Zacks Equity Research

argenx's (ARGX) lead pipeline candidate, efgartigimod, meets primary endpoint in a pivotal study evaluating it in myasthenia gravis. A BLA is likely to be filed by the end of 2020.

Why Halozyme (HALO) Could Be Positioned for a Surge

by Zacks Equity Research

Halozyme (HALO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.